<DOC>
	<DOCNO>NCT01733836</DOCNO>
	<brief_summary>To determine whether use metformin patient low-risk prostate cancer delay progression clinically significant prostate cancer .</brief_summary>
	<brief_title>Prostate Cancer Active Surveillance Metformin Trial</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Willing able provide inform consent Men &gt; = 18 year age , le 80 Men biopsy proven , lowrisk , localized prostate cancer ( define ) Men choose expectant management primary treatment prostate cancer Diagnostic biopsy perform within 4 month screen visit Gleason score ≤ 6 3 core less Gleason pattern 4 , less 50 % core involved cancer Clinical stage T1cT2a ( Initial diagnosis T1a/T1b obtain TURP allow ) Serum PSA ≤10 ng/mL Life expectancy great 5 year Normal kidney hepatic function define follow criterion : Total bilirubin le 1.5 X institutional upper limit normal ( ULN ) AST ( SGOT ) /ALT ( SGPT ) less 1.5 X institutional ULN Alkaline phosphatase le 2 X institutional ULN Creatinine le 1.4 X institutional ULN Able swallow retain oral medication No exposure metformin within 12 month randomization No known hypersensitivity intolerance metformin hydrochloride No condition associate increase risk metformin hydrochlorideassociated lactic acidosis ( e.g. , congestive heart failure define NYHA class III IV function status , history acidosis type , habitual intake ≥ 3 alcoholic beverage per day , age great 80 ) English fluency allow patient report outcomes completion Any previous prostate cancer treatment ( radiotherapy , chemotherapy , hormonal therapy , oral glucocorticoid , GnRH analogues ) Diabetes include type 1 diabetes . Patients know type 2 diabetes eligible provide metformin previous 12 month pharmacological agent . Concurrent previous use anabolic steroid drug anti androgenic property include 5ARIs ( dutasteride finasteride ) Prostate volume great 80 cc . ( per TRUS biopsy report ) Prostatic surgery procedure within 3 month screen visit Severe BPH symptom ( IPSS ≥25 , ≥20 already αblocker therapy ) Other malignancy , exception adequately treat nonmelanoma skin cancer , NMIBC solid tumor curatively treat evidence disease ≥ 5 year Planned concurrent participation interventional randomized trial include exercise The presence coexistent medical condition opinion investigator would potential significantly limit adherence medication , ability absorb medication include limited psychiatric condition , malabsorption syndrome severe ischemic heart disease Known hypersensitivity intolerance metformin Concurrent plan participation randomize trial weight loss exercise intervention trial target insulin , IGF1 receptor , PI3K inhibitor .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>